CRISPR Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
CRISPR Therapeutics has a total shareholder equity of $2.1B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.4B and $355.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$2.11b |
Equity | US$2.08b |
Total liabilities | US$355.08m |
Total assets | US$2.44b |
Recent financial health updates
We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08Recent updates
Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts
Aug 09CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M
Aug 08Crispr Therapeutics' Continued Progress Warrants A Buy
Jul 25Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Term
Jun 23Financial Position Analysis
Short Term Liabilities: CRSP's short term assets ($2.1B) exceed its short term liabilities ($119.0M).
Long Term Liabilities: CRSP's short term assets ($2.1B) exceed its long term liabilities ($236.1M).
Debt to Equity History and Analysis
Debt Level: CRSP is debt free.
Reducing Debt: CRSP had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRSP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CRSP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.